Saini-Chohan Harjot K, Holmes Michael G, Chicco Adam J, Taylor William A, Moore Russell L, McCune Sylvia A, Hickson-Bick Diane L, Hatch Grant M, Sparagna Genevieve C
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
J Lipid Res. 2009 Aug;50(8):1600-8. doi: 10.1194/jlr.M800561-JLR200. Epub 2008 Nov 10.
Cardiolipin (CL) is responsible for modulation of activities of various enzymes involved in oxidative phosphorylation. Although energy production decreases in heart failure (HF), regulation of cardiolipin during HF development is unknown. Enzymes involved in cardiac cardiolipin synthesis and remodeling were studied in spontaneously hypertensive HF (SHHF) rats, explanted hearts from human HF patients, and nonfailing Sprague Dawley (SD) rats. The biosynthetic enzymes cytidinediphosphatediacylglycerol synthetase (CDS), phosphatidylglycerolphosphate synthase (PGPS) and cardiolipin synthase (CLS) were investigated. Mitochondrial CDS activity and CDS-1 mRNA increased in HF whereas CDS-2 mRNA in SHHF and humans, not in SD rats, decreased. PGPS activity, but not mRNA, increased in SHHF. CLS activity and mRNA decreased in SHHF, but mRNA was not significantly altered in humans. Cardiolipin remodeling enzymes, monolysocardiolipin acyltransferase (MLCL AT) and tafazzin, showed variable changes during HF. MLCL AT activity increased in SHHF. Tafazzin mRNA decreased in SHHF and human HF, but not in SD rats. The gene expression of acyl-CoA: lysocardiolipin acyltransferase-1, an endoplasmic reticulum MLCL AT, remained unaltered in SHHF rats. The results provide mechanisms whereby both cardiolipin biosynthesis and remodeling are altered during HF. Increases in CDS-1, PGPS, and MLCL AT suggest compensatory mechanisms during the development of HF. Human and SD data imply that similar trends may occur in human HF, but not during nonpathological aging, consistent with previous cardiolipin studies.
心磷脂(CL)负责调节参与氧化磷酸化的各种酶的活性。尽管心力衰竭(HF)时能量产生减少,但HF发展过程中心磷脂的调节尚不清楚。我们在自发性高血压HF(SHHF)大鼠、人类HF患者的离体心脏以及未发生衰竭的Sprague Dawley(SD)大鼠中研究了参与心脏心磷脂合成和重塑的酶。对生物合成酶胞苷二磷酸二酰甘油合成酶(CDS)、磷脂酰甘油磷酸合成酶(PGPS)和心磷脂合成酶(CLS)进行了研究。HF时线粒体CDS活性和CDS-1 mRNA增加,而SHHF大鼠和人类中的CDS-2 mRNA减少,SD大鼠中未减少。SHHF大鼠中PGPS活性增加,但mRNA未增加。SHHF大鼠中CLS活性和mRNA减少,但人类中mRNA无显著变化。心磷脂重塑酶单溶血心磷脂酰基转移酶(MLCL AT)和塔法辛在HF期间表现出不同变化。SHHF大鼠中MLCL AT活性增加。SHHF大鼠和人类HF中塔法辛mRNA减少,但SD大鼠中未减少。内质网MLCL AT酰基辅酶A:溶血心磷脂酰基转移酶-1的基因表达在SHHF大鼠中未改变。这些结果提供了HF期间心磷脂生物合成和重塑均发生改变的机制。CDS-1、PGPS和MLCL AT的增加提示HF发展过程中的代偿机制。人类和SD大鼠的数据表明,人类HF中可能出现类似趋势,但在非病理性衰老过程中不会出现,这与之前的心磷脂研究一致。